Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-11-2008

Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies

Authors: PD Dr. Andrea Schmitt, Eleni Parlapani, Oliver Gruber, Thomas Wobrock, Peter Falkai

Published in: European Archives of Psychiatry and Clinical Neuroscience | Special Issue 5/2008

Abstract

To a large extend schizophrenia has been shown to be heritable, with neuregulin-1 (NRG1) one of the candidate genes considered to play a role in the pathophysiology of the disorder. While several polymorphisms within this gene have been reported to be associated with schizophrenia, the impact of NRG1 risk genotypes on disturbed brain function and symptoms of the disease is unknown and might be elucidated using post-mortem studies. Neuregulins are signalling proteins and the NRG1 family encodes at least 15 different splice variants, classified into four isoforms. They play an important role in cell differentiation, migration, myelination and proliferation of oligodendrocytes and neurons. Dysfunction in these processes may be related to neurodevelopmental disturbances in schizophrenia. NRG1 isoforms are differentially expressed in relevant brain regions of schizophrenia patients such as the prefrontal cortex and hippocampus and may contribute to pathophysiological processes. Different NRG1 genotypes have been shown to influence gene expression of isoforms and the risk-associated variants are in primarily non-coding and promoter regions, probably operating by altering gene expression or splicing. In addition, NRG1 regulates the expression of the nicotinic acetylcholine receptor, and expression of the γ-aminobutyric acid (GABA_A) and N-methyl-d-aspartate receptor in the brain. However, the contribution of NRG1 risk genotypes to expression of isoforms and cognitive or psychotic symptoms in patients remain to be investigated in prospective post-mortem studies. In animal models of ischemia/hypoxia, NRG1 has been shown to act as a therapeutic, neuroprotective agent and should be investigated in more detail in transgenic animal models.

Available only for authorised users

Addington AM, Gornick MC, Shaw P, Seal J, Gogtay N, Greenstein D, Clasen L, Coffey M, Gochman P, Long R et al (2007) Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. Mol Psychiatry 12:195–205PubMedCrossRef

Badner JA, Gershon ES (2002) Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 7:405–411PubMedCrossRef

Bakker SC, Hoogendoorn ML, Selten JP, Verduijn W, Pearson PL, Sinke RJ, Kahn RS (2004) Neuregulin 1: genetic support for schizophrenia subtypes. Mol Psychiatry 9:1061–1063PubMedCrossRef

Bertram I, Bernstein HG, Lendeckel U, Bukowska A, Dobrowolny H, Keilhoff G, Kanakis D, Mawrin C, Bielau H, Falkai P et al (2007) Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y Acad Sci 1096:147–156PubMedCrossRef

Buonanno A, Fischbach GD (2001) Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol 11:287–296PubMedCrossRef

Cannon TD, Kaprio J, Lonnqvist J, Huttunen M, Koskenvuo M (1998) The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 55:67–74PubMedCrossRef

Canoll PD, Kraemer R, Teng KK, Marchionni MA, Salzer JL (1999) GGF/neuregulin induces a phenotypic reversion of oligodendrocytes. Mol Cell Neurosci 13:79–94PubMedCrossRef

Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL (1996) GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 17:229–243PubMedCrossRef

Corvin AP, Morris DW, McGhee K, Schwaiger S, Scully P, Quinn J, Meagher D, Clair DS, Waddington JL, Gill M (2004) Confirmation and refinement of an ‘at-risk’ haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol Psychiatry 9:208–213PubMedCrossRef

10.

Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V (2006) Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21:531–540PubMedCrossRef

11.

Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132–191PubMedCrossRef

12.

Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5–40PubMedCrossRef

13.

Falls DL (2003) Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284:14–30PubMedCrossRef

14.

Fukui N, Muratake T, Kaneko N, Amagane H, Someya T (2006) Supportive evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a Japanese population. Neurosci Lett 396:117–120PubMedCrossRef

15.

Georgieva L, Dimitrova A, Ivanov D, Nikolov I, Williams NM, Grozeva D, Zaharieva I, Toncheva D, Owen MJ, Kirov G et al (2008) Support for Neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry 6:6

16.

Green A, Ellis KA, Ellis J, Bartholomeusz CF, Ilic S, Croft RJ, Phan KL, Nathan PJ (2005) Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav 81:575–584PubMedCrossRef

17.

Guo WP, Wang J, Li RX, Peng YW (2006) Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia. Brain Res 1087:180–185PubMedCrossRef

18.

Gurling HM, Kalsi G, Brynjolfson J, Sigmundsson T, Sherrington R, Mankoo BS, Read T, Murphy P, Blaveri E, McQuillin A et al (2001) Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21–22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3–24 and 20q12.1–11.23. Am J Hum Genet 68:661–673PubMedCrossRef

19.

Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98:4746–4751PubMedCrossRef

20.

Hall D, Gogos JA, Karayiorgou M (2004) The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 3:240–248PubMedCrossRef

21.

Hall H, Lawyer G, Sillen A, Jonsson EG, Agartz I, Terenius L, Arnborg S (2007) Potential genetic variants in schizophrenia: a Bayesian analysis. World J Biol Psychiatry 8:12–22PubMedCrossRef

22.

Harrison PJ, Law AJ (2006) Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60:132–140PubMedCrossRef

23.

Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR (2004) Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 9:299–307PubMedCrossRef

24.

Hong CJ, Huo SJ, Liao DL, Lee K, Wu JY, Tsai SJ (2004) Case-control and family-based association studies between the neuregulin 1 (Arg38Gln) polymorphism and schizophrenia. Neurosci Lett 366:158–161PubMedCrossRef

25.

Kampman O, Anttila S, Illi A, Saarela M, Rontu R, Mattila KM, Leinonen E, Lehtimaki T (2004) Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 15:2517–2520PubMedCrossRef

26.

Lachman HM, Pedrosa E, Nolan KA, Glass M, Ye K, Saito T (2006) Analysis of polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 141B:102–109PubMedCrossRef

27.

Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR (2006) Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proc Natl Acad Sci USA 103:6747–6752PubMedCrossRef

28.

Li B, Woo RS, Mei L, Malinow R (2007) The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 54:583–597PubMedCrossRef

29.

Li D, Collier DA, He L (2006) Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15:1995–2002PubMedCrossRef

30.

Li T, Stefansson H, Gudfinnsson E, Cai G, Liu X, Murray RM, Steinthorsdottir V, Januel D, Gudnadottir VG, Petursson H et al (2004) Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry 9:698–704PubMed

31.

Liu Y, Ford B, Mann MA, Fischbach GD (2001) Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci 21:5660–5669PubMed

32.

Liu Y, Ford BD, Mann MA, Fischbach GD (2005) Neuregulin-1 increases the proliferation of neuronal progenitors from embryonic neural stem cells. Dev Biol 283:437–445PubMedCrossRef

33.

Mathew SV, Law AJ, Lipska BK, Davila-Garcia MI, Zamora ED, Mitkus SN, Vakkalanka R, Straub RE, Weinberger DR, Kleinman JE et al (2007) Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet 16:2921–2932PubMedCrossRef

34.

McIntosh AM, Moorhead TW, Job D, Lymer GK, Munoz Maniega S, McKirdy J, Sussmann JE, Baig BJ, Bastin ME, Porteous D et al (2007) The effects of a neuregulin 1 variant on white matter density and integrity. Mol Psychiatry 9:9

35.

Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE, Birchmeier C (1997) Isoform-specific expression and function of neuregulin. Development 124:3575–3586PubMed

36.

Munafo MR, Attwood AS, Flint J (2008) Neuregulin 1 genotype and schizophrenia. Schizophr Bull 34:9–12PubMedCrossRef

37.

Munafo MR, Thiselton DL, Clark TG, Flint J (2006) Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 11:539–546PubMedCrossRef

38.

Nadri C, Belmaker RH, Agam G (2007) Oxygen restriction of neonate rats elevates neuregulin-1alpha isoform levels: possible relationship to schizophrenia. Neurochem Int 51:447–450PubMedCrossRef

39.

Nave KA, Salzer JL (2006) Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol 16:492–500PubMedCrossRef

40.

Ozaki M, Sasner M, Yano R, Lu HS, Buonanno A (1997) Neuregulin-beta induces expression of an NMDA-receptor subunit. Nature 390:691–694PubMed

41.

Parlapani E, Schmitt A, Wirths O, Bauer M, Sommer C, Rueb U, Skowronek MH, Treutlein J, Petroianu GA, Rietschel M et al (2008) Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World J Biol Psychiatry 7:1–8CrossRef

42.

Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR, Morley CP, McGann L, Gentile KL, Rockwell GN, Medeiros HM, Carvalho C, Macedo A, Dourado A, Valente J, Ferreira CP, Patterson NJ, Azevedo MH, Daly MJ, Pato CN, Pato MT, Sklar P (2004) Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 16:16

43.

Propping P, Nothen MM, Korner J, Rietschel M, Maier W (1994) Genetic association in psychiatric diseases. Concepts and findings. Nervenarzt 65:725–740PubMed

44.

Rieff HI, Raetzman LT, Sapp DW, Yeh HH, Siegel RE, Corfas G (1999) Neuregulin induces GABA(A) receptor subunit expression and neurite outgrowth in cerebellar granule cells. J Neurosci 19:10757–10766PubMed

45.

Rosa A, Gardner M, Cuesta MJ, Peralta V, Fatjo-Vilas M, Miret S, Navarro ME, Comas D, Fananas L (2007) Family-based association study of neuregulin-1 gene and psychosis in a Spanish sample. Am J Med Genet B Neuropsychiatr Genet 144B:954–957PubMedCrossRef

46.

Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692–695PubMedCrossRef

47.

Segal D, Koschnick JR, Slegers LH, Hof PR (2007) Oligodendrocyte pathophysiology: a new view of schizophrenia. Int J Neuropsychopharmacol 10:503–511PubMedCrossRef

48.

Stefanis NC, Trikalinos TA, Avramopoulos D, Smyrnis N, Evdokimidis I, Ntzani EE, Ioannidis JP, Stefanis CN (2007) Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol Psychiatry 62:784–792PubMedCrossRef

49.

Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C et al (2003) Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72:83–87PubMedCrossRef

50.

Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT et al (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877–892PubMedCrossRef

51.

Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, Nakamura R, Kakita A, Takahashi H, Nawa H (2004) Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci 1025:84–91PubMedCrossRef

52.

Tang JX, Chen WY, He G, Zhou J, Gu NF, Feng GY, He L (2004) Polymorphisms within 5′ end of the Neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. Mol Psychiatry 9:11–12PubMedCrossRef

53.

Thomson PA, Christoforou A, Morris SW, Adie E, Pickard BS, Porteous DJ, Muir WJ, Blackwood DH, Evans KL (2007) Association of Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population. Mol Psychiatry 12:94–104PubMedCrossRef

54.

Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S (2007) Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol 10:557–563PubMedCrossRef

55.

Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798–805PubMedCrossRef

56.

Walss-Bass C, Liu W, Lew DF, Villegas R, Montero P, Dassori A, Leach RJ, Almasy L, Escamilla M, Raventos H (2006) A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. Biol Psychiatry 60:548–553PubMedCrossRef

57.

Walss-Bass C, Raventos H, Montero AP, Armas R, Dassori A, Contreras S, Liu W, Medina R, Levinson DF, Pereira M, Leach RJ, Almasy L, Escamilla MA (2006) Association analyses of the neuregulin 1 gene with schizophrenia and manic psychosis in a Hispanic population. Acta Psychiatr Scand 113:314–321PubMedCrossRef

58.

Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S, O’Donovan MC, Owen MJ (2003) Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry 8:485–487PubMedCrossRef

59.

Woo RS, Li XM, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J, Neiswender H, Dong XP, Wu J, Gassmann M, Lai C, Xiong WC, Gao TM, Mei L (2007) Neuregulin-1 enhances depolarization-induced GABA release. Neuron 54:599–610PubMedCrossRef

60.

Xu Z, Jiang J, Ford G, Ford BD (2004) Neuregulin-1 is neuroprotective and attenuates inflammatory responses induced by ischemic stroke. Biochem Biophys Res Commun 322:440–446PubMedCrossRef

61.

Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL, Zhou M, Zhang HY, Kong QM, Liu C et al (2003) Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry 8:706–709PubMedCrossRef

62.

Zhao X, Shi Y, Tang J, Tang R, Yu L, Gu N, Feng G, Zhu S, Liu H, Xing Y et al (2004) A case control and family based association study of the neuregulin1 gene and schizophrenia. J Med Genet 41:31–34PubMedCrossRef

Title: Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies
Authors: PD Dr. Andrea Schmitt
Eleni Parlapani
Oliver Gruber
Thomas Wobrock
Peter Falkai
Publication date: 01-11-2008
Publisher: D. Steinkopff-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue Special Issue 5/2008
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-008-5019-x

At a glance: The STEP trials

Springer Medicine

Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 5/2008

Psychiatric symptoms in Parkinson’s disease

On the road to DSM-V and ICD-11

Psychiatry as a diagnostic discipline

From genes to psychoses and back: the role of the 5HT2α-receptor and prepulse inhibition in schizophrenia

Imaging the deluded brain

Operationalized psychodynamic diagnosis in planning and evaluating the psychotherapeutic process